Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks

By afschroeder • May 10, 2026

Sofen HL, Gogineni R, Nishandar T, Bagel J. Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks. Dermatol Ther (Heidelb). 2026 May 9. doi: 10.1007/s13555-026-01774-2. Epub ahead of print. PMID: 42105056.

Tags: Dermatology, Investigator Global Assessment modified 2011 of the scalp (IGA mod 2011 [scalp]) score, Obesity, Olive View DoM, plaque psoriasis, Psoriasis Scalp Severity Index (PSSI), Publications, scalp psoriasis, tildrakizumab

Response to Barnawi et al., “Bullous pemphigoid in the era of immunotherapy: Implications for treatment algorithms”

Kasperkiewicz M, Adotama P, Tomayko MM, Culton DA. Response to Barnawi et al., "Bullous pemphigoid in the era of immunotherapy: Implications for treatment algorithms". J[...]

Multi-cytokine based TWAS for seven inflammatory skin disorders identify candidate causal genes in keratinocytes

Zhang H, Patrick MT, Sarkar MK, Bogle R, Li Q, Uppala R, Perez White BE, Petukhova L, Dand N, Stuart PE, Christiano AM, Simpson MA,[...]

Increased risk of spontaneous abortion risk with alopecia areata independent of antiphospholipid syndrome and endometritis

Podolsky AS, Singal A, Goh C, Lipner SR. Increased risk of spontaneous abortion risk with alopecia areata independent of antiphospholipid syndrome and endometritis. J Am[...]